CILcare
Cilcare is a biotech company dedicated to harnessing auditory sciences to improve early diagnosis and targeted treatment of hearing-related diseases. They support partners in developing therapies for auditory disorders such as inherited hearing loss, synaptopathy, ototoxicity, sensorineural hearing loss, and tinnitus. Cilcare emphasizes scientific excellence, innovation, and collaboration to advance precision medicine in audiology, with a focus on early detection of neurocognitive, inflammatory, and age-related diseases linked to hearing health. The company is actively engaged in auditory analytics, early diagnosis, and targeted therapies, leveraging digital biomarkers and advanced research to transform hearing healthcare.
Industries
Nr. of Employees
small (1-50)
CILcare
Montpellier, Languedoc-Roussillon, France, Europe
Products
Portfolio of proprietary auditory therapeutics (4 candidates)
A set of four acquired proprietary drug candidates focused on treating cochlear synaptopathy and related auditory disorders.
Lead preclinical-to-clinical candidate for cochlear synaptopathy (lead compound)
Lead small-molecule candidate intended to restore synaptic connections and auditory nerve activity; planned for early-phase clinical studies (Phase 1b/2a) with intratympanic administration.
Portfolio of proprietary auditory therapeutics (4 candidates)
A set of four acquired proprietary drug candidates focused on treating cochlear synaptopathy and related auditory disorders.
Lead preclinical-to-clinical candidate for cochlear synaptopathy (lead compound)
Lead small-molecule candidate intended to restore synaptic connections and auditory nerve activity; planned for early-phase clinical studies (Phase 1b/2a) with intratympanic administration.
Services
Preclinical efficacy and GLP ototoxicity testing
End-to-end preclinical efficacy studies and GLP-compliant toxicology/toxicokinetic testing to assess safety and effectiveness of compounds and devices for inner-ear indications.
In vitro and ex vivo screening assays
Otic cell-line screening and cochlear explant assays for early-stage toxicity and efficacy assessment, supplemented with zebrafish screening models for rapid throughput.
Animal models and behavioral testing
Development and execution of species-appropriate animal models (noise-induced hearing loss, synaptopathy, ototoxicity, tinnitus models) with behavioral and functional readouts.
Electrophysiology and auditory functional testing
Objective functional testing services including ABR, DPOAE, CAP and unicellular electrophysiology for preclinical and translational studies.
Pathology, histology and imaging
Histological processing and quantitative analysis of auditory tissues with cytocochleogram generation and microscopy workflows to quantify structural outcomes.
Inner-ear PK and bioanalysis
Tissue-level pharmacokinetic distribution studies and bioanalysis tailored to inner-ear exposure, including vector distribution analyses to inform dosing and delivery.
Preclinical efficacy and GLP ototoxicity testing
End-to-end preclinical efficacy studies and GLP-compliant toxicology/toxicokinetic testing to assess safety and effectiveness of compounds and devices for inner-ear indications.
In vitro and ex vivo screening assays
Otic cell-line screening and cochlear explant assays for early-stage toxicity and efficacy assessment, supplemented with zebrafish screening models for rapid throughput.
Animal models and behavioral testing
Development and execution of species-appropriate animal models (noise-induced hearing loss, synaptopathy, ototoxicity, tinnitus models) with behavioral and functional readouts.
Electrophysiology and auditory functional testing
Objective functional testing services including ABR, DPOAE, CAP and unicellular electrophysiology for preclinical and translational studies.
Pathology, histology and imaging
Histological processing and quantitative analysis of auditory tissues with cytocochleogram generation and microscopy workflows to quantify structural outcomes.
Inner-ear PK and bioanalysis
Tissue-level pharmacokinetic distribution studies and bioanalysis tailored to inner-ear exposure, including vector distribution analyses to inform dosing and delivery.
Expertise Areas
- Preclinical translational models for hearing disorders
- Inner-ear drug delivery and microsurgery
- Auditory functional phenotyping and biomarker development
- GLP toxicology and regulatory study support for otic indications
Key Technologies
- Auditory brainstem response (ABR)
- Distortion-product otoacoustic emissions (DPOAE)
- Wave I–V and compound action potential (CAP) analysis
- Behavioral auditory assays (GPIAS, PPI, startle reflex)